Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?

Matarraz, Sergio; Paiva, Bruno; Díez-Campelo, María; López-Corral, Lucía; Mateos, Maria Victoria; Hernández, Mª Teresa; Orfao, Alberto; San Miguel, Jesús F.

Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?

This is an open-access paper.-- et al.

Detalles Bibliográficos
Autores:	Matarraz, Sergio, Paiva, Bruno, Díez-Campelo, María, López-Corral, Lucía, Mateos, Maria Victoria, Hernández, Mª Teresa, Orfao, Alberto, San Miguel, Jesús F.
Tipo de recurso:	artículo
Estado:	Versión publicada
Fecha de publicación:	2012
País:	España
Institución:	Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:	DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:	oai:digital.csic.es:10261/134241
Acceso en línea:	http://hdl.handle.net/10261/134241
Access Level:	acceso abierto
Palabra clave:	Diagnosis Lenalidomide Bone marrow cells Multiple myeloma Phenotypic alterations

id	ES_e087fc6b5ebb54390a25da60dcdaff73
oai_identifier_str	oai:digital.csic.es:10261/134241
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?Matarraz, SergioPaiva, BrunoDíez-Campelo, MaríaLópez-Corral, LucíaMateos, Maria VictoriaHernández, Mª TeresaOrfao, AlbertoSan Miguel, Jesús F.DiagnosisLenalidomideBone marrow cellsMultiple myelomaPhenotypic alterationsThis is an open-access paper.-- et al.Increased risk of acute myeloid leukemia/myelodysplastic syndromes following treatment has been reported in multiple myeloma, but whether dysplastic features are already present at diagnosis remains to be investigated. Using multiparameter flow cytometry, we analyzed the distribution and phenotype of bone marrow hematopoietic cells from 47 multiple myeloma patients (15 symptomatic and 32 high-risk smoldering). From the 32 smoldering myeloma patients, 18 were studied at baseline and 22 after nine cycles of lenalidomide/dexamethasone treatment following the QUIREDEX trial (including 8 from baseline). Phenotypic alterations of bone marrow cells of 7 (47%) symptomatic and 6 (33%) smoldering myeloma patients were detected at baseline; there was no difference in the frequency and extent of phenotypic alterations between symptomatic versus smoldering cases. Likewise, no difference was seen between smoldering myeloma patients studied at baseline versus after lenalidomide/dexamethasone treatment. Our results suggest that phenotypic alterations of bone marrow hematopoietic cells are often present in newly diagnosed symptomatic and smoldering multiple myeloma patients. QUIREDEX trial (NCT00480363)This work was supported by the Cooperative Research Thematic Network (RTICs; RD06/0020/0006, RD06/0020/0005, RD06/0020/0035, RD06/0020/0031, and G03/136), Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria (FIS: PI060339; 06/1354; 02/0905; 01/0089/01-02; PS09/01897) and Consejería de Educación (GR37) and Consejería de Sanidad (557/A/10), Junta de Castilla y León, Valladolid, Spain.Peer ReviewedFerrata Storti FoundationJunta de Castilla y LeónRed Temática de Investigación Cooperativa en Cáncer (España)Instituto de Salud Carlos IIIConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]2016201620122016info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10261/134241reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttp://dx.doi.org/10.3324/haematol.2012.064121Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/1342412026-05-22T06:33:51Z
dc.title.none.fl_str_mv	Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?
title	Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?
spellingShingle	Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide? Matarraz, Sergio Diagnosis Lenalidomide Bone marrow cells Multiple myeloma Phenotypic alterations
title_short	Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?
title_full	Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?
title_fullStr	Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?
title_full_unstemmed	Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?
title_sort	Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?
dc.creator.none.fl_str_mv	Matarraz, Sergio Paiva, Bruno Díez-Campelo, María López-Corral, Lucía Mateos, Maria Victoria Hernández, Mª Teresa Orfao, Alberto San Miguel, Jesús F.
author	Matarraz, Sergio
author_facet	Matarraz, Sergio Paiva, Bruno Díez-Campelo, María López-Corral, Lucía Mateos, Maria Victoria Hernández, Mª Teresa Orfao, Alberto San Miguel, Jesús F.
author_role	author
author2	Paiva, Bruno Díez-Campelo, María López-Corral, Lucía Mateos, Maria Victoria Hernández, Mª Teresa Orfao, Alberto San Miguel, Jesús F.
author2_role	author author author author author author author
dc.contributor.none.fl_str_mv	Junta de Castilla y León Red Temática de Investigación Cooperativa en Cáncer (España) Instituto de Salud Carlos III Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv	Diagnosis Lenalidomide Bone marrow cells Multiple myeloma Phenotypic alterations
topic	Diagnosis Lenalidomide Bone marrow cells Multiple myeloma Phenotypic alterations
description	This is an open-access paper.-- et al.
publishDate	2012
dc.date.none.fl_str_mv	2012 2016 2016 2016
dc.type.none.fl_str_mv	info:eu-repo/semantics/article http://purl.org/coar/resource_type/c_6501 Publisher's version info:eu-repo/semantics/publishedVersion
format	article
status_str	publishedVersion
dc.identifier.none.fl_str_mv	http://hdl.handle.net/10261/134241
url	http://hdl.handle.net/10261/134241
dc.language.none.fl_str_mv	Inglés
language_invalid_str_mv	Inglés
dc.relation.none.fl_str_mv	http://dx.doi.org/10.3324/haematol.2012.064121 Sí
dc.rights.none.fl_str_mv	info:eu-repo/semantics/openAccess
eu_rights_str_mv	openAccess
dc.publisher.none.fl_str_mv	Ferrata Storti Foundation
publisher.none.fl_str_mv	Ferrata Storti Foundation
dc.source.none.fl_str_mv	reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str	Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str	DIGITAL.CSIC. Repositorio Institucional del CSIC
collection	DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869422210815361024
score	15.812429

Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?

Similares en LA Referencia